Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection

Journal of Infection

Volumn 66, Issue 4, 2013, Pages 357-365

  Mihret, Adane ^a,b,c   Bekele, Yonas ^a   Bobosha, Kidest ^a   Kidd, Martin ^d   Aseffa, Abraham ^a   Howe, Rawleigh ^a   Walzl, Gerhard ^c  

^a ARMAUER HANSEN RESEARCH INSTITUTE   (Ethiopia)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Active tuberculosis; Cytokines; Differentiation; Latent infection

Indexed keywords

CHEMOKINE; CYTOKINE; EPIDERMAL GROWTH FACTOR; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 3;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EX VIVO STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CHEMOKINES; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HIV INFECTIONS; HUMANS; LATENT TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84875539764     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.11.005     Document Type: Article

References (22)

1. Diel R., Goletti D., Ferrara G., Bothamley G., Cirillo D., Kampmann B., et al. Interferon-{gamma} release assays for the diagnosis of latent M. tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011, 37:88-99.
2. Demissie A., Abebe M., Aseffa A., Rook G., Fletcher H., Zumla A., et al. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol 2004, 172(11):6938-6943.
3. Sutherland J., De Jong B., Jeffries D., Adetifa I., Ota M. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS One 2010, 5(8):e12365.
4. Juffermans N., Verbon A., Van Deventer S., Van Deutekom H., Belisle J., Ellis M., et al. Elevated chemokine concentrations in sera of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients with tuberculosis: a possible role for mycobacterial lipoarabinomannan. Infect Immun 1999, 67(8):4295-4297.
5. Azzurri A., Oy Sow, Amedei A., Bah B., Diallo S., Peri G., et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005, 7(1):1-8.
6. Siawaya J., Beyers N., Van Helden P., Gerhard W. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin Exp Immunol 2009, 156:69-77.
7. Wassie L., Demissie A., Aseffa A., Abebe M., Yamuah L., Tilahun H., et al. Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time. PLoS One 2008, 3(1):e1522.
8. Chegou N., Black G., Kidd M., Van Helden P., Walzl G. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med 2009, 9:21.
9. Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticci M, et al. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb);91(3):260-7.
10. QuantiFERON-TB Gold In-Tube: technical information. http://www.cellestis.com.
11. Siawaya J., Chegou N., Van Den Heuvel M., Diacon A., Nulda Beyers M., Helden P., et al. Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. Cytokine 2009, 47:132-136.
12. Alessandri A., Souza A., Oliveira S., Macedo G., Teixeira M., Teixeira A. Concentrations of CXCL8, CXCL9 and sTNFR1 in plasma of patients with pulmonary tuberculosis undergoing treatment. Inflamm Res 2006, 55(12):528-533.
13. Ruhwald M., Bodmer T., Maier C., Jepsen M., Haaland M., Eugen-Olsen J., et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008, 32(6):1607-1615.
14. Kabeer B.S., Sikhamanib R., Rajaa A. Comparison of interferon gamma and interferon gamma-inducible protein-10 secretion in HIV-tuberculosis patients. AIDS 2010, 24:323-325.
15. Belard E., Semb S., Ruhwald M., Werlinrud A., Soborg B., Jensen F., et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011, 17:2340-2349.
16. Luster A., Ravetch J. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987, 166(4):1084-1097.
17. Narumi S., Yoneyama H., Inadera H., Nishioji K., Itoh Y., Okanoue T., et al. TNF-alpha is a potent inducer for IFN-inducible protein-10 in hepatocytes and unaffected by GM-CSF in vivo, in contrast to IL-1beta and IFN-gamma. Cytokine 2000, 12(7):1007-1016.
18. Ruhwald M., Bjerregaard-Andersen M., Rabna P., Eugen-Olsen J., Pernille R. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 2009, 2:19.
19. Goletti D, Raja A, Kabeer BS, Rodrigues C, Sodha A, Butera O, et al. IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J Infect;61(2):133-43.
20. Whittaker E., Gordon A., Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFN γ?. PLoS One 2008, 3:e3901.
21. Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, Rianda A, et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect;65(1):49-59.
22. Kabeer BS, Raja A, Raman B, Thangaraj S, Leportier M, Ippolito G, et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis;11:135.